Larimar Therapeutics. has been granted a patent for methods and compositions to measure the activity of frataxin (FXN) proteins, including fusion proteins. The patent details a specific method for assessing FXN enzymatic activity through the generation of reactive oxygen species (ROS). GlobalData’s report on Larimar Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Larimar Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Larimar Therapeutics's grant share as of June 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for measuring frataxin protein activity and modulation
The granted patent US11988675B2 outlines a method for measuring the enzymatic activity of Frataxin (FXN) protein, specifically focusing on the generation of reactive oxygen species (ROS). The method involves combining the FXN protein with a reducing agent and an ROS detector compound to create an assay mixture. The amount of ROS produced is measured over time, allowing for the determination of enzymatic parameters related to the FXN protein's activity. The claims detail various conditions for the assay, including pH adjustments, the presence or absence of metal ions, and specific types of reducing agents and ROS detector compounds.
Further claims specify the types of metal ions that can be included, such as Mn2+, Fe3+, Zn2+, Cu2+, and Mg2+, and the nature of the reducing agents, which may include organic compounds like hydroquinone. The patent also describes methods for determining specific enzymatic parameters, such as maximum initial velocity and unit activity of the FXN protein. Additionally, the patent encompasses quality control methods for FXN protein samples, utilizing the described assay to measure enzymatic activity. Overall, the patent provides a comprehensive framework for assessing FXN protein activity, which may have implications for research and therapeutic applications related to conditions associated with FXN dysfunction.
To know more about GlobalData’s detailed insights on Larimar Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
